CN1748682A - 治疗慢性鼻炎的奥苯达唑鼻腔凝胶剂 - Google Patents
治疗慢性鼻炎的奥苯达唑鼻腔凝胶剂 Download PDFInfo
- Publication number
- CN1748682A CN1748682A CN 200410078456 CN200410078456A CN1748682A CN 1748682 A CN1748682 A CN 1748682A CN 200410078456 CN200410078456 CN 200410078456 CN 200410078456 A CN200410078456 A CN 200410078456A CN 1748682 A CN1748682 A CN 1748682A
- Authority
- CN
- China
- Prior art keywords
- nasal
- oxibendazole
- rhinitis
- chronic
- treatment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 206010039083 rhinitis Diseases 0.000 title claims abstract description 43
- 201000009151 chronic rhinitis Diseases 0.000 title claims abstract description 18
- 229940100652 nasal gel Drugs 0.000 title claims description 22
- RAOCRURYZCVHMG-UHFFFAOYSA-N N-(6-propoxy-1H-benzimidazol-2-yl)carbamic acid methyl ester Chemical compound CCCOC1=CC=C2N=C(NC(=O)OC)NC2=C1 RAOCRURYZCVHMG-UHFFFAOYSA-N 0.000 claims abstract description 48
- 229960002762 oxibendazole Drugs 0.000 claims abstract description 46
- 239000004615 ingredient Substances 0.000 claims description 3
- 235000015110 jellies Nutrition 0.000 abstract description 4
- 238000002360 preparation method Methods 0.000 abstract description 3
- 239000008274 jelly Substances 0.000 abstract 2
- 241000158526 Nasalis Species 0.000 description 23
- 230000001684 chronic effect Effects 0.000 description 22
- KWGRBVOPPLSCSI-WPRPVWTQSA-N (-)-ephedrine Chemical compound CN[C@@H](C)[C@H](O)C1=CC=CC=C1 KWGRBVOPPLSCSI-WPRPVWTQSA-N 0.000 description 14
- 206010028748 Nasal obstruction Diseases 0.000 description 14
- 210000003928 nasal cavity Anatomy 0.000 description 12
- 210000002850 nasal mucosa Anatomy 0.000 description 12
- 210000004877 mucosa Anatomy 0.000 description 11
- 230000001969 hypertrophic effect Effects 0.000 description 10
- 201000010099 disease Diseases 0.000 description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 9
- 239000007788 liquid Substances 0.000 description 9
- 238000003756 stirring Methods 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- KWGRBVOPPLSCSI-UHFFFAOYSA-N d-ephedrine Natural products CNC(C)C(O)C1=CC=CC=C1 KWGRBVOPPLSCSI-UHFFFAOYSA-N 0.000 description 7
- 229960002179 ephedrine Drugs 0.000 description 7
- 210000003097 mucus Anatomy 0.000 description 7
- 210000001944 turbinate Anatomy 0.000 description 7
- 208000000592 Nasal Polyps Diseases 0.000 description 6
- 239000003814 drug Substances 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 208000016366 nasal cavity polyp Diseases 0.000 description 6
- 239000007923 nasal drop Substances 0.000 description 6
- 239000007922 nasal spray Substances 0.000 description 6
- 208000024891 symptom Diseases 0.000 description 6
- 239000007924 injection Substances 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- 238000009423 ventilation Methods 0.000 description 5
- 206010020880 Hypertrophy Diseases 0.000 description 4
- 206010061218 Inflammation Diseases 0.000 description 4
- 201000007100 Pharyngitis Diseases 0.000 description 4
- 206010061926 Purulence Diseases 0.000 description 4
- 206010044302 Tracheitis Diseases 0.000 description 4
- 230000002421 anti-septic effect Effects 0.000 description 4
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 4
- 229940097572 chloromycetin Drugs 0.000 description 4
- 239000012153 distilled water Substances 0.000 description 4
- 239000000499 gel Substances 0.000 description 4
- 210000001331 nose Anatomy 0.000 description 4
- 239000003229 sclerosing agent Substances 0.000 description 4
- 230000028327 secretion Effects 0.000 description 4
- 230000008961 swelling Effects 0.000 description 4
- 238000002560 therapeutic procedure Methods 0.000 description 4
- 238000005303 weighing Methods 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 3
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 3
- 229920003091 Methocel™ Polymers 0.000 description 3
- 206010061876 Obstruction Diseases 0.000 description 3
- 206010006451 bronchitis Diseases 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 230000003203 everyday effect Effects 0.000 description 3
- 230000008014 freezing Effects 0.000 description 3
- 238000007710 freezing Methods 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 3
- 229940071826 hydroxyethyl cellulose Drugs 0.000 description 3
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 3
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 3
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 3
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 3
- 229960003943 hypromellose Drugs 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 210000000492 nasalseptum Anatomy 0.000 description 3
- 239000000523 sample Substances 0.000 description 3
- 230000035807 sensation Effects 0.000 description 3
- 239000007921 spray Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- CNIIGCLFLJGOGP-UHFFFAOYSA-N 2-(1-naphthalenylmethyl)-4,5-dihydro-1H-imidazole Chemical compound C=1C=CC2=CC=CC=C2C=1CC1=NCCN1 CNIIGCLFLJGOGP-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 208000017667 Chronic Disease Diseases 0.000 description 2
- 206010011224 Cough Diseases 0.000 description 2
- 201000004624 Dermatitis Diseases 0.000 description 2
- 102000002322 Egg Proteins Human genes 0.000 description 2
- 108010000912 Egg Proteins Proteins 0.000 description 2
- 206010062717 Increased upper airway secretion Diseases 0.000 description 2
- 244000061176 Nicotiana tabacum Species 0.000 description 2
- 235000002637 Nicotiana tabacum Nutrition 0.000 description 2
- 206010039085 Rhinitis allergic Diseases 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 201000010105 allergic rhinitis Diseases 0.000 description 2
- 230000000507 anthelmentic effect Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 208000037976 chronic inflammation Diseases 0.000 description 2
- 208000037893 chronic inflammatory disorder Diseases 0.000 description 2
- 230000008602 contraction Effects 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 210000000981 epithelium Anatomy 0.000 description 2
- 210000003128 head Anatomy 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 229940097496 nasal spray Drugs 0.000 description 2
- 210000005036 nerve Anatomy 0.000 description 2
- 210000004681 ovum Anatomy 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- 208000026435 phlegm Diseases 0.000 description 2
- 230000035790 physiological processes and functions Effects 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 210000004876 tela submucosa Anatomy 0.000 description 2
- 238000002691 topical anesthesia Methods 0.000 description 2
- 239000005526 vasoconstrictor agent Substances 0.000 description 2
- DNXIKVLOVZVMQF-UHFFFAOYSA-N (3beta,16beta,17alpha,18beta,20alpha)-17-hydroxy-11-methoxy-18-[(3,4,5-trimethoxybenzoyl)oxy]-yohimban-16-carboxylic acid, methyl ester Natural products C1C2CN3CCC(C4=CC=C(OC)C=C4N4)=C4C3CC2C(C(=O)OC)C(O)C1OC(=O)C1=CC(OC)=C(OC)C(OC)=C1 DNXIKVLOVZVMQF-UHFFFAOYSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- 206010001229 Adenoidal hypertrophy Diseases 0.000 description 1
- 241000498253 Ancylostoma duodenale Species 0.000 description 1
- 241001465677 Ancylostomatoidea Species 0.000 description 1
- 201000008283 Atrophic Rhinitis Diseases 0.000 description 1
- 208000000412 Avitaminosis Diseases 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 102000019034 Chemokines Human genes 0.000 description 1
- 108010012236 Chemokines Proteins 0.000 description 1
- 206010009137 Chronic sinusitis Diseases 0.000 description 1
- 206010009152 Chronic tonsillitis Diseases 0.000 description 1
- 208000003322 Coinfection Diseases 0.000 description 1
- 101800004637 Communis Proteins 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- 206010013952 Dysphonia Diseases 0.000 description 1
- -1 Equitac Chemical compound 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 206010020565 Hyperaemia Diseases 0.000 description 1
- 206010021135 Hypovitaminosis Diseases 0.000 description 1
- 208000001705 Mouth breathing Diseases 0.000 description 1
- 206010067993 Mucosal necrosis Diseases 0.000 description 1
- 206010028735 Nasal congestion Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 208000006735 Periostitis Diseases 0.000 description 1
- LCQMZZCPPSWADO-UHFFFAOYSA-N Reserpilin Natural products COC(=O)C1COCC2CN3CCc4c([nH]c5cc(OC)c(OC)cc45)C3CC12 LCQMZZCPPSWADO-UHFFFAOYSA-N 0.000 description 1
- QEVHRUUCFGRFIF-SFWBKIHZSA-N Reserpine Natural products O=C(OC)[C@@H]1[C@H](OC)[C@H](OC(=O)c2cc(OC)c(OC)c(OC)c2)C[C@H]2[C@@H]1C[C@H]1N(C2)CCc2c3c([nH]c12)cc(OC)cc3 QEVHRUUCFGRFIF-SFWBKIHZSA-N 0.000 description 1
- 206010057190 Respiratory tract infections Diseases 0.000 description 1
- 206010039088 Rhinitis atrophic Diseases 0.000 description 1
- 206010039101 Rhinorrhoea Diseases 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- 244000061458 Solanum melongena Species 0.000 description 1
- 206010046306 Upper respiratory tract infection Diseases 0.000 description 1
- 206010070488 Upper-airway cough syndrome Diseases 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- GZCGUPFRVQAUEE-SLPGGIOYSA-N aldehydo-D-glucose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O GZCGUPFRVQAUEE-SLPGGIOYSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- 229940124599 anti-inflammatory drug Drugs 0.000 description 1
- 239000002220 antihypertensive agent Substances 0.000 description 1
- 229940127088 antihypertensive drug Drugs 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 239000004568 cement Substances 0.000 description 1
- 208000027157 chronic rhinosinusitis Diseases 0.000 description 1
- 210000000589 cicatrix Anatomy 0.000 description 1
- 210000004081 cilia Anatomy 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 239000002817 coal dust Substances 0.000 description 1
- 208000027744 congestion Diseases 0.000 description 1
- 238000002681 cryosurgery Methods 0.000 description 1
- GRIXGZQULWMCLU-UHFFFAOYSA-L disodium;7-[[2-carboxylato-2-(4-hydroxyphenyl)acetyl]amino]-7-methoxy-3-[(1-methyltetrazol-5-yl)sulfanylmethyl]-8-oxo-5-oxa-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate Chemical compound [Na+].[Na+].C12OCC(CSC=3N(N=NN=3)C)=C(C([O-])=O)N2C(=O)C1(OC)NC(=O)C(C([O-])=O)C1=CC=C(O)C=C1 GRIXGZQULWMCLU-UHFFFAOYSA-L 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 201000010934 exostosis Diseases 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 235000013312 flour Nutrition 0.000 description 1
- 210000001061 forehead Anatomy 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 201000010930 hyperostosis Diseases 0.000 description 1
- 230000001709 ictal effect Effects 0.000 description 1
- 238000007373 indentation Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 230000008338 local blood flow Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000000116 mitigating effect Effects 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 229960005016 naphazoline Drugs 0.000 description 1
- 208000010753 nasal discharge Diseases 0.000 description 1
- 201000009240 nasopharyngitis Diseases 0.000 description 1
- 208000004296 neuralgia Diseases 0.000 description 1
- IAIWVQXQOWNYOU-FPYGCLRLSA-N nitrofural Chemical compound NC(=O)N\N=C\C1=CC=C([N+]([O-])=O)O1 IAIWVQXQOWNYOU-FPYGCLRLSA-N 0.000 description 1
- 229960000349 nitrofural Drugs 0.000 description 1
- 210000004279 orbit Anatomy 0.000 description 1
- VRYKTHBAWRESFI-VOTSOKGWSA-N oxantel Chemical compound CN1CCCN=C1\C=C\C1=CC=CC(O)=C1 VRYKTHBAWRESFI-VOTSOKGWSA-N 0.000 description 1
- 229960000535 oxantel Drugs 0.000 description 1
- 230000036407 pain Effects 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 210000003460 periosteum Anatomy 0.000 description 1
- 230000002688 persistence Effects 0.000 description 1
- 238000000554 physical therapy Methods 0.000 description 1
- MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
- 229960004919 procaine Drugs 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- BJOIZNZVOZKDIG-MDEJGZGSSA-N reserpine Chemical compound O([C@H]1[C@@H]([C@H]([C@H]2C[C@@H]3C4=C([C]5C=CC(OC)=CC5=N4)CCN3C[C@H]2C1)C(=O)OC)OC)C(=O)C1=CC(OC)=C(OC)C(OC)=C1 BJOIZNZVOZKDIG-MDEJGZGSSA-N 0.000 description 1
- 229960003147 reserpine Drugs 0.000 description 1
- MDMGHDFNKNZPAU-UHFFFAOYSA-N roserpine Natural products C1C2CN3CCC(C4=CC=C(OC)C=C4N4)=C4C3CC2C(OC(C)=O)C(OC)C1OC(=O)C1=CC(OC)=C(OC)C(OC)=C1 MDMGHDFNKNZPAU-UHFFFAOYSA-N 0.000 description 1
- 231100000241 scar Toxicity 0.000 description 1
- 108010048734 sclerotin Proteins 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 201000009890 sinusitis Diseases 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 229960005491 sodium morrhuate Drugs 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 208000027765 speech disease Diseases 0.000 description 1
- 238000009628 steelmaking Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 206010044008 tonsillitis Diseases 0.000 description 1
- 210000003901 trigeminal nerve Anatomy 0.000 description 1
- 230000024883 vasodilation Effects 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- 208000030401 vitamin deficiency disease Diseases 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本发明涉及使用奥苯达唑制备鼻腔凝胶剂,以及奥苯达唑的鼻腔凝胶剂在治疗慢性鼻炎中的应用。
Description
本发明涉及使用奥苯达唑制备鼻腔凝胶剂,以及奥苯达唑的鼻腔凝胶剂在治疗慢性鼻炎中的应用。
一、慢性鼻炎简介I
慢性鼻炎(chronic rh initis)是鼻腔粘膜和粘膜下层的慢性炎症。表现为鼻粘膜的慢性充血肿胀,称慢性单纯性鼻炎(chronic simple rhinitis)。若发展为鼻粘膜和鼻甲骨的增生肥厚,称慢性肥厚性鼻炎(chronic hypertrophic rhinitis)。
(一)病因
1.局部病因
(1)急性鼻炎反复发作或治疗不彻底而演变成慢性鼻炎。
(2)由于邻近的慢性炎症长期刺激或畸形,致鼻发生通气不畅或引流阻塞,如慢性鼻窦炎、鼻中隔偏曲、慢性扁桃体炎或腺样体肥大等。
(3)鼻腔用药不当或过量过久形成药物性鼻炎(rhinitis medicamentosa),常见于久用滴鼻净之后。
2.全身病因
(1)长期慢性疾病,如内分泌失调、长期便秘、肾脏病和心血管疾病等,而致鼻粘膜长期或屡发性充血或瘀血。
(2)维生素缺乏,如维生素A或C。
(3)烟酒过度可影响鼻粘膜血管舒缩而发生障碍。
(4)长期服用利血平等降压药物,可引起鼻腔血管扩张而产生似鼻炎的症状。
3.环境因素:在有水泥、烟草、煤尘、面粉或化学物质等环境中的工作者,鼻粘膜受到物理和化学因子的刺激与损害,可造成慢性鼻炎。温湿度急剧变化的环境,如炼钢、冷冻、烘熔等车间工人,也较易发生此病。
(二)治疗原则 消炎消肿,通气引流和尽量维护鼻粘膜的生理功能,同时要注意对病因的处理。
二、慢性单纯性鼻炎
(一)病理粘膜深层血管慢性扩张,尤以下鼻甲海绵状血窦变化最明显。粘液腺功能活跃,分泌增多。鼻甲粘膜肿胀,但粘膜下组织无明显增生性改变。
(二)临床表现
1.鼻塞:间歇性或交替性。①间歇性鼻塞:一般表现为白天、劳动或运动时减轻,夜间、静坐或寒冷时加重。②交替性鼻塞:侧卧时位于下侧的鼻腔常阻塞加重;转卧另一侧后,刚才位于上侧没有鼻塞或鼻塞较轻的鼻腔,转到下侧后出现鼻塞或鼻塞加重;而刚才位于下侧的鼻腔鼻塞减轻。此外,嗅觉可有不同程度的减退,说话呈闭塞性鼻音。由于鼻涕长期流经鼻前庭和上唇部,可致皮炎或湿疹,多见于小孩。鼻涕向后可流入咽腔,出现咳嗽、多痰等症状。
2.多涕:常为粘液性或粘脓性,偶呈脓性。脓性者多于继发性感染后出现。
3.检查:鼻粘膜肿胀,表面光滑、湿润,一般呈暗红色。鼻甲粘膜柔软而富有弹性,探针轻压可现凹陷,但移开探针则凹陷很快复原,特别在下鼻甲为明显。若用1~2%麻黄素液作鼻粘膜收缩,则鼻甲迅速缩小。总鼻道或下鼻道有粘液性或脓性分泌物。
(三)治疗 治疗原则为恢复鼻腔通气功能,排除分泌物,根除病因。
1.1%麻黄素或呋喃西林麻黄素液、氯霉素麻黄素液滴鼻,每日3次,
2.0.25~0.5%普鲁卡因作鼻丘封闭或下鼻甲粘膜下封闭,每次1~1.5ml,隔日1次,或每周2次,5次为一疗程。
3.超短波或红外线理疗,可改善局部血循环以减轻症状。
4.经上述疗法无效时,可选用硬化剂作下鼻甲注射治疗。
5.找出与疾病有关的病因并及时治疗。锻炼身体增强机体抵抗力。
三、慢性肥厚性鼻炎
慢性肥厚性鼻炎(chronic hypertrophic rhinitis)为鼻粘膜、粘膜下层及鼻甲骨的增生肥厚性改变,一般由慢性单纯性鼻炎发展而来。
(一)病理 粘膜上皮纤毛脱落,变为复层立方上皮,粘膜下层由水肿继而发生纤维组织增生而使粘膜肥厚,久之,可呈桑椹状或息肉样变,骨膜及骨组织增生,鼻甲骨骨质也可呈肥大改变。
(二)临床表现
1.鼻塞较重,多为持续性、常张口呼吸,嗅觉多减退。
2.鼻涕稠厚,多呈粘液性或粘脓性。由于鼻涕后流,刺激咽喉致有咳嗽、多痰。
3.当肥大的中鼻甲压迫鼻中隔时,可引起三叉神经眼支所分出的筛前神经受压或炎症,出现不定期发作性额部疼痛,并向鼻梁和眼眶放射,称筛前神经痛,又称筛前神经综合症。
4.检查:①下鼻甲明显肥大,或下鼻甲与中鼻甲均肥大,常致鼻腔堵塞。鼻腔底部或下鼻道有粘液性或粘脓性分泌物。②粘膜肿胀,呈粉红色或紫红色,表面不平,或呈结节状或桑椹状,尤以下鼻甲前端及其游离缘为明显。探针轻压凹陷不明显,触之有硬实感。③局部用血管收缩剂后粘膜收缩不明显。
(三)治疗
1.血管收缩剂滴鼻液的应用,限于轻型病例。
2.下鼻甲粘膜下硬化剂注射,其作用机理为硬化剂注射后,可使局部发生化学性炎性反应,产生疤痕组织,缩小鼻甲体积,改善通气。常用50%葡萄糖液加15%氯化钠溶液、5%鱼肝油酸钠或80%甘油等。鼻甲表面麻醉后,用22~23号细长针头从下鼻甲下缘前端平行向后刺入,勿刺通粘膜,边退针边注射硬化剂,直至针头拔出为止。亦可于下鼻甲前端、中部、后端分3次注射,每侧注射0.5ml,每10天1次,以3~5次为一疗程。
3.下鼻甲粘膜下电凝固肥厚的粘膜组织,使产生疤痕收缩。在表面麻醉后,电针头从下鼻甲前端刺入,凝固20~30秒钟后拔出,电流为10~30毫安。
4.冷冻手术,是将特制的冷冻头置于下鼻甲表面做冷冻,每次1~2分钟,使病变粘膜坏死脱落而再生粘膜。
5.手术疗法,一般治疗无效,或粘膜显著肥厚,或肥厚部分位于下鼻甲后端或下缘,可行下鼻甲部分切除术或中鼻甲部分切除术。下鼻甲切除不宜过多,原则上不超过下鼻甲的1/3,以免影响鼻粘膜功能或继发萎缩性鼻炎。骨性肥大者,宜行下鼻甲粘-骨膜下切除术,既可改善鼻腔的通气引流,又无损于鼻粘膜的生理功能。
6.对全身慢性疾病或邻近病灶如鼻中隔偏曲或鼻窦炎等,亦给予适当治疗。
四、奥苯达唑简介
奥苯达唑,英文通用名称:Oxibendazole;一般名称:奥苯达唑、丙氧咪唑、Oxibendazole、Equitac、Loditac、Oxibendazolum;化学名:5-丙氧基-苯并咪唑-2-氨基甲酸甲酯。为广谱驱虫药。可影响虫体多种生化代谢途径。对蛔虫、钩虫和鞭虫均有明显驱虫作用。与其它驱钩虫药比较,本品不但对十二指肠钩虫疗效好,对美洲钩虫也有较好疗效。2日和3日疗法的虫卵转阴率可达56%-100%。一般驱虫药对鞭虫疗效差,奥克太尔驱鞭虫时虫卵转阴率虽可达70%,但对钩虫和蛔虫无效;而本品不仅对钩虫和蛔虫有效,驱鞭虫的疗效也可达70%左右。。
五、迄今,国内外都尚未见任何将奥苯达唑用于治疗慢性鼻炎的报道或文献记载。
本发明将奥苯达唑作为单独的有效成分或与其它药物一起配成复方,制成鼻腔凝胶剂。
本发明所述的用奥苯达唑或用含奥苯达唑的复方制成的鼻腔凝胶剂的适应症,包括,但不限于以下病症:鼻息肉或鼻息肉病、鼻炎、咽炎、气管炎和支气管炎。
使用本发明所述的用奥苯达唑或用含奥苯达唑的复方制成的鼻腔凝胶剂,对于鼻息肉或鼻息肉病患者,直接鼻腔给药,可有效地使大的鼻息肉缩小,使小的鼻息肉消失;或于鼻息肉切除术后给药,可阻止鼻息肉的复发;对于鼻炎、咽炎、气管炎和支气管炎,可以缓解炎症症状。
本发明所述的鼻腔凝胶剂,为喷鼻剂的一中,系指在喷鼻剂中加入能增加药液粘度的辅料,使药液能更好地粘附于鼻粘膜上,从而使有药物能从药液中缓慢或持续释放。所述的能增加药液粘度的辅料,包括,但不限于:各种规格或类型的卡泊普(Carbopol)、各种规格或类型的羟甲基纤维素、各种规格或类型的羟乙基纤维素、各种规格或类型的羟丙甲纤维素等。
本发明所述的慢性鼻炎,是本领域的技术人员所熟知的,现代的医学书籍中有其准确的定义。
本发明所述的过敏性鼻炎、咽炎、气管炎和支气管炎,也是本领域的技术技术人员所熟知的,现代的医学书籍中有其准确的定义。
通过以下实施例对本发明的奥苯达唑鼻腔凝胶剂的制备,及其在治疗慢性鼻炎中的应用进行描述。需说明的是,下述实施例只是用来说明而非限制本发明,本领域技术人员所熟知的通过其他给药途径将奥苯达唑用于治疗过敏性鼻炎、慢性鼻炎、咽炎、气管炎和支气管炎的技术均在本发明的范围内。
实施例1采用卡泊普制备奥苯达唑鼻腔凝胶剂
称取卡泊普940(Carbopol940)2g;取100ml 80℃左右的无菌蒸馏水;边搅拌边向热水中加入卡泊普,全部加入卡泊普后,持续搅拌12h。待温度降低后,加入100mg奥苯达唑,再加入适量防腐剂,再搅拌30min后,及得奥苯达唑凝胶,分装到鼻腔喷雾剂瓶中或滴鼻剂瓶中,即得奥苯达唑鼻腔凝胶剂。
实施例2采用羟甲基纤维素制备奥苯达唑鼻腔凝胶剂
称取羟甲基纤维素2g;取100ml 80℃左右的无菌蒸馏水;边搅拌边向热水中加入卡泊普,全部加入卡泊普后,持续搅拌12h。待温度降低后,加入100mg奥苯达唑,再加入适量防腐剂,再搅拌30min后,及得奥苯达唑凝胶,分装到鼻腔喷雾剂瓶中或滴鼻剂瓶中,即得奥苯达唑鼻腔凝胶剂。
实施例3采用羟乙基纤维素制备奥苯达唑鼻腔凝胶剂
称取羟乙基纤维素2g;取100ml 80℃左右的无菌蒸馏水;边搅拌边向热水中加入卡泊普,全部加入卡泊普后,持续搅拌12h。待温度降低后,加入100mg奥苯达唑,再加入适量防腐剂,再搅拌30min后,及得奥苯达唑凝胶,分装到鼻腔喷雾剂瓶中或滴鼻剂瓶中,即得奥苯达唑鼻腔凝胶剂。
实施例4采用羟丙甲纤维素制备奥苯达唑鼻腔凝胶剂
称取羟丙甲纤维素2g;取100ml 80℃左右的无菌蒸馏水;边搅拌边向热水中加入卡泊普,全部加入卡泊普后,持续搅拌12h。待温度降低后,加入100mg奥苯达唑,再加入适量防腐剂,再搅拌30min后,及得奥苯达唑凝胶,分装到鼻腔喷雾剂瓶中或滴鼻剂瓶中,即得奥苯达唑鼻腔凝胶剂。
实施例5奥苯达唑鼻腔凝胶剂治疗慢性鼻炎
奥苯达唑鼻腔凝胶剂治疗慢性鼻炎15例,取得了显著的临床效果。
一般资料 门诊病例25例,其中男12例,女13例;年龄21~54岁,平均32岁。患者病程13个月至5年。慢性单纯性鼻炎9例,慢性肥厚性鼻炎16例。所有病例均曾接受其他药物治疗。
治疗方法 患者随机分为奥苯达唑治疗组(15例,其中慢性单纯性鼻炎5例,慢性肥厚性鼻炎10例)和对照组(10例,其中慢性单纯性鼻炎4例,慢性肥厚性鼻炎6例)。奥苯达唑治疗组,采用奥苯达唑鼻腔凝胶剂治疗,每天鼻腔给药喷二次,剂量为100ug/0.1ml每喷。对照组用0.25%氯霉素麻黄素液,滴鼻或喷入鼻腔,每日三次,每次3~5滴。两组疗程均为4周,期间禁用其他抗炎药物及其他类型的滴鼻剂。
疗效评价标准 以末次随访时检查情况为标准。痊愈:鼻塞症状完全消失,鼻腔完全恢复通气,鼻分泌物及嗅觉亦有改善,下鼻甲明显缩小。好转:鼻塞明显改善,仅在上呼吸道感染或侧卧时有轻微鼻塞现象,下鼻甲较治疗前有不同程度缩小。无效:随访时间内鼻塞无改善,下鼻甲无改变。
结果 两组治疗后1周、2周、1个月及3个月分别随访4次,以后不定期随访。随访时间长者9个月,最短者1个月,平均随访4个月。
奥苯达唑治疗组15例患者中,有慢性单纯性鼻炎5例(痊愈3例,好转2例,总有效率100%);有慢性肥厚性鼻炎10例(痊愈4例,好转5例,无效1例,总有效率90%)。
0.25%氯霉素麻黄素液对照组112例患者中,有慢性单纯性鼻炎4例(痊愈1例,好转1例,无效2例,总有效率50%);有慢性肥厚性鼻炎6例(痊愈0例,好转4例,无效2例,总有效率66.7%)。
因此,奥苯达唑治疗慢性鼻炎的有效率高,疗效高于0.25%氯霉素麻黄素液。
实施例6奥苯达唑鼻腔凝胶剂治疗慢性鼻炎个案
某男,40岁,患慢性鼻炎12年,头痛、头晕、鼻塞,使用奥苯达唑鼻腔凝胶剂行鼻局部吸入治疗,15天后症状消失。随访观察30天,未见复发。以后除感冒时再无鼻炎症状。
Claims (2)
1.将奥苯达唑作为有效成分或有效成分之一制成的鼻腔凝胶剂。
2.奥苯达唑在用于治疗慢性鼻炎的鼻腔凝胶剂的生产中的应用。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 200410078456 CN1748682A (zh) | 2004-09-14 | 2004-09-14 | 治疗慢性鼻炎的奥苯达唑鼻腔凝胶剂 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 200410078456 CN1748682A (zh) | 2004-09-14 | 2004-09-14 | 治疗慢性鼻炎的奥苯达唑鼻腔凝胶剂 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN1748682A true CN1748682A (zh) | 2006-03-22 |
Family
ID=36604461
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN 200410078456 Pending CN1748682A (zh) | 2004-09-14 | 2004-09-14 | 治疗慢性鼻炎的奥苯达唑鼻腔凝胶剂 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN1748682A (zh) |
-
2004
- 2004-09-14 CN CN 200410078456 patent/CN1748682A/zh active Pending
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2004078201A1 (en) | Treatment of sinusitis related chronic facial pain and headache with botulinum toxin | |
CN1559508A (zh) | 防治咽喉炎症的药物及制备方法 | |
CN1284585C (zh) | 治疗急慢性咽喉炎、复发性口腔溃疡的药物及制备方法 | |
CN103656025A (zh) | 一种跌打药酒 | |
CN100364530C (zh) | 治疗慢性鼻炎的左旋咪唑 | |
CN1748682A (zh) | 治疗慢性鼻炎的奥苯达唑鼻腔凝胶剂 | |
CN1748692A (zh) | 治疗慢性鼻炎的阿苯达唑鼻腔凝胶剂 | |
CN104383173A (zh) | 一种治疗面瘫的中药汤剂 | |
CN1748687A (zh) | 治疗慢性鼻炎的奥苯达唑新剂型 | |
CN1748677A (zh) | 治疗慢性鼻炎的甲苯咪唑新剂型 | |
CN1771981A (zh) | 一种痔疮膏 | |
CN1256959C (zh) | 治疗鼻炎的药膏 | |
CN1748697A (zh) | 治疗慢性鼻炎的阿苯达唑新剂型 | |
CN1772098A (zh) | 一种治疗慢性咽炎及痰热症的中药组合物及其制备工艺 | |
CN1751686A (zh) | 治疗慢性鼻炎的阿司咪唑新剂型 | |
CN1259939C (zh) | 一种治疗口腔疾病的中药制剂及制备方法 | |
CN1130202C (zh) | 复方滴鼻液及其制备方法 | |
CN105412315A (zh) | 一种治疗扁桃体及淋巴结炎症的中药组合物膏剂 | |
CN1911227A (zh) | 左旋咪唑新剂型及其新用途 | |
CN1176688C (zh) | 一种治疗急慢性咽炎的药物及其制备方法 | |
CN105056060A (zh) | 一种用于治疗慢性鼻窦炎的药物 | |
CN103751614A (zh) | 一种治疗放射性口腔粘膜炎的中药组合物 | |
CN107536974A (zh) | 一种治疗急慢性上颌窦炎的中药组合物 | |
CN103720875B (zh) | 一种治疗慢性鼻炎的中药膏贴剂及其制备方法 | |
CN110585282A (zh) | 一种鼻窦炎散及制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C41 | Transfer of patent application or patent right or utility model | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20070302 Address after: No. 12, Huayuan Road, Jiangsu, Nanjing Applicant after: Jiangsu Simcere Pharmaceutical Research Company Limited Address before: 5C, building six, 6 District, far road, century garden, Beijing, Haidian District Applicant before: Wang Heyao Co-applicant before: Zheng Wenjie |
|
C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
WD01 | Invention patent application deemed withdrawn after publication |